The Use of Sodium Pyrophosphate to Improve a Translucent Clay Simulate

In the ever expanding quest to understand the nature and behavior of soil, translucent and even transparent media have been developed to serve as soil simulates. These artificial soils can be used in experimental models to make visual measurement of phenomena such as geosystem kinematics, soil mass movement, soil particle motion, and pore fluid flow that would be nearly impossible to obtain in natural opaque soils without expensive equipment or boundary effects. One successful type of translucent clay simulate is lithium sodium magnesium silicate (LNM silicate); however, it’s low density/high void ratio results in higher than typical permeability, low undrained shear strength, and extremely long consolidation times. Until now, translucent soil simulates of only 4.5% by mass LNM silicate to total mass have been possible. This paper provides a method for creating mixtures of translucent LNM silicate gel/glass as high as 15% by mass with the additions of an emulsifier, sodium pyrophosphate decahydrate (SPP), which impedes gelation so additional silicate powder can be added. Further, digital image processing techniques are used to present a relationship between LNM silicate, SPP, and translucency and an analysis of the modified simulate’s permeability and consolidation properties, with comparisons to natural clays, is also included.The lead author would like to acknowledge the excellent work of the undergraduate researchers on this project: Elliese Shaughnessy for the laboratory work and MATLAB programming necessary to create the Laponite-SPP curve, Kristen Ewert for conducting and interpreting the consolidation experiments, Nicholas Boardman for mixing the testing specimens and conducting the permeability experiments, and Tom Anderson for assisting with the permeability experiments. We would also like to thank Dr. Cassandra Rutherford for her assistance on the project. This research was funded through the National Science Foundation, Award Number: 1041604.This is the author accepted manuscript. The final version is available from American Society of Civil Engineers via http://dx.doi.org/10.1061/9780784480151.00

Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 µg ethinyl estradiol and 3 mg drospirenone

BACKGROUND: The objective of this study was to compare cycle control, cycle-related characteristics and bodyweight effects of NuvaRing with those of a combined oral contraceptive (COC) containing 30 µg of ethinyl estradiol and 3 mg of drospirenone. METHODS: A randomized, multicentre, open-label trial in which 983 women were treated (intent-to-treat population) with NuvaRing or the COC for 13 cycles. RESULTS: Breakthrough bleeding or spotting during cycles 2-13 was in general less frequent with NuvaRing than that with the COC (4.7-10.4%) and showed a statistically significant odds ratio of 0.61 (95% confidence interval: 0.46, 0.80) with longitudinal analysis. Intended bleeding was significantly better for all cycles with NuvaRing (55.2-68.5%) than that with the COC (35.6-56.6%) (P < 0.01). Changes from baseline in mean bodyweight and body composition parameters were relatively small for both groups with no notable between-group differences. CONCLUSION: NuvaRing was associated with better cycle control than the COC, and there was no clinically relevant difference between the two groups in bodyweigh

International Federation for Professionals in Abortion and Contraception (FIAPAC)

FIAPAC (Fédération Internationale des Associés Professionels de l’Avortement et de la Contraception) is an organisation, founded in 1997 and registered in France. We are now an international organisation, with over 270 members around the world. Our members come from a wide range of disciplines working in abortion care: counsellors, administrators, nurses, doctors, policymakers, researchers, women's groups, global leaders in reproductive health, lawyers and ethicists

Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone

BACKGROUND: The objective of this study was to compare cycle control, cycle-related characteristics and bodyweight effects of NuvaRing with those of a combined oral contraceptive (COC) containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. METHODS: A randomized, multicentre, open-label trial in which 983 women were treated (intent-to-treat population) with NuvaRing or the COC for 13 cycles. RESULTS: Breakthrough bleeding or spotting during cycles 2-13 was in general less frequent with NuvaRing than that with the COC (4.7-10.4%) and showed a statistically significant odds ratio of 0.61 (95% confidence interval: 0.46, 0.80) with longitudinal analysis. Intended bleeding was significantly better for all cycles with NuvaRing (55.2-68.5%) than that with the COC (35.6-56.6%) (P < 0.01). Changes from baseline in mean bodyweight and body composition parameters were relatively small for both groups with no notable between-group differences. CONCLUSION: NuvaRing was associated with better cycle control than the COC, and there was no clinically relevant difference between the two groups in bodyweight